HGH Fragment 176-191
Also known as: HGH Frag, Fragment 176-191, AOD
limited human dataWADA bannedNot FDA approvedResearch only
Published Dose Range
Low250 mcg/dose
Typical500 mcg 1-2x/day
High1000 mcg/day total
C-terminal fragment of hGH. Claimed fat-loss action without the GH/IGF-1 anabolic effects. Most human dosing is anecdotal.
Published Cycle Range
Short4 wks
Typical8 wks
Long12 wks
Typical cut-phase use. Limited long-term human data.
Off-cycle: 4 weeks
Administration
Routessubcutaneous
Frequency1-2x daily
Preferred timingMorning fasted + pre-workout
AvoidAvoid carbs/fats within 1 hour
Timing mirrors GHRP protocols.
Safety Profile
Contraindications
- • Pregnancy
- • Cancer history
Common side effects
- • Injection site reactions
- • Flushing
- • Mild nausea
Serious risks
- • Limited long-term safety data
Pregnancy / breastfeeding
No data — consult clinician
Common Misconceptions
- Often conflated with AOD-9604 (AOD is the modified analog with a disulfide bridge)
- Not a GH agonist — does not stimulate IGF-1 or grow tissue
Commonly Stacked With
AOD-9604CJC-1295BPC-157
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.